https://pbs.twimg.com/media/FhhUEK7XkAIpQrw.png
Kavanaugh et al. TYK2i deucravacitinib in PsA. Nice breakdown of MDA and its components over 16 weeks. MDA achieved 23-24% with deucravacitinib at 16 weeks vs 8% with placebo @RheumNow #ACR22 Abstr#2136 https://t.co/9IG8CeZzMh https://t.co/Vg8E20y7Z8

Links:

Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in a Phase 2 T… https://acrabstracts.org/abstract/deucravacitinib-an-oral-selective-tyrosine-ki…
Richard Conway
RichardPAConway
14-11-2022
×